Monitoring vancomycin in an intensive care unit: A retrospective survey on 66 patients;Monitorage de la vancomycine en réanimation: Étude rétrospective de 66 patients

Medecine et Maladies Infectieuses

Volumn 41, Issue 8, 2011, Pages 410-414

  Commandeur, D ^a   Giacardi, C ^a   Danguy Des Deserts, M ^a   Huynh, S ^a   Buguet Brown, M L ^a   Ould Ahmed, M ^a   Drouillard, I ^a  

^a Military Teaching Hospital Clermont Tonnerre   (France)

Author keywords

Dosage antibiotique; Intensive care unit; Pharmacokinetics; Propri t s pharmacocin tiques; R animation; Therapeutic drug monitoring; Toxicit ; Toxicity; Vancomycin; Vancomycine

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; GRAM POSITIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG MONITORING; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 79961030813     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.01.012     Document Type: Article

References (16)

1. Garrafo R., Lavrut T. Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation. Reanimation 2005, 14:264-275.
2. Veber B, Martin C, Montravers P, Lepape A, Gauzit R, Granry JC, et al. Antibiothérapie probabiliste des états septiques graves. Conférence d'experts; 2004.
3. Gérard A., Larche J. Place des glycopeptides en réanimation. Med Mal Infect 2004, 34:S97-S98.
4. MacGowan A.P. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998, 20:473-477.
5. Domart Y. Principes thérapeutiques des infections à staphylocoques. Places et limites des thérapeutiques classiques. AFAR 2002, 21:392-398.
6. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-12.
7. Craig W.A. Does the dose matter?. Clin Infect Dis 2001, 33(Suppl. 3):S233-S237.
8. Potel G., Caillon J., Jacqueline C., Navas D., Kergueris M.F., Batard E. Dosage des antibiotiques en réanimation: quand et comment demander et interpréter les tests ?. Reanimation 2006, 15:187-192.
9. Schortgen F. Néphrotoxicité et médicaments. Reanimation 2005, 14(5):436-441.
10. Roberts J.A., Lippman J. Antibacterial dosing in intensive care. Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45(8):755-773.
11. Gous A.G., Dance M.D., Lipman J., Luyt D.K., MathivhaR, Scribante J. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995, 23(6):678-682.
12. Mariani-Kurkdjian P., Nebbad H., Aujard Y., Bingen E. Surveillance des taux sériques de vancomycine dans le traitement des infections à staphylocoque en pédiatrie. Arch Pediatr 2008, 15:1625-1629.
13. Vuagna A., Stern R., Lotthe A., Schuhmacher H., Duong M., Hoffmeyer P., et al. High dose vancomycine for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004, 29:351-357.
14. Rello J., Sole-Violan J., Sa-Borges M., Garnacho-Montero J., Muñoz E., Sirgo G., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33(9):1983-1987.
15. Wysocki M., Delatour F., Faurisson F., Rauss A., PeanY, Misset B., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467.
16. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. A report from the NNIS System. Am J Infect Control 2003, 31:481-498. CDC NNIS System.